<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Flow cytometry (FCM) is a reproducible and objective technique that may be useful in the diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by detecting abnormal immunophenotypes specific to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated 5 granulocyte/monocyte panels by FCM to find a sensitive and specific combination of panels in order to discriminate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from non-clonal <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow aspirates from 35 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 25 patients with non-clonal <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> were studied </plain></SENT>
<SENT sid="3" pm="."><plain>We performed FCM using 5 granulocyte/monocyte panels (CD15/CD10/CD45, CD64/CD33/CD45, CD16/CD13/CD45, CD16/CD11b/CD45, and CD56/CD19/CD7/CD45) to examine the positive rate in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and controls, and to find an optimal combination that maximizes the detection rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the number of abnormal immunophenotypes per 5 granulocytic and 5 monocytic panels were 2.1 ± 1.2 and 2.2 ± 1.4 </plain></SENT>
<SENT sid="5" pm="."><plain>The rates were higher than the controls (P&lt; 0.001, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>As the number of employed panels increased, the percent values of abnormal immunophenotypes increased (P=0.002) </plain></SENT>
<SENT sid="7" pm="."><plain>The maximum rate of abnormal immunophenotype was 89.7% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, especially 100.0% in <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype, when a combination of three panels, CD15/CD10/CD45, CD64/CD33/CD45, and either CD16/CD13/CD45 or CD16/CD11b/CD45 was used </plain></SENT>
<SENT sid="8" pm="."><plain>This study demonstrates that a combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b granulocyte panels in FCM is sensitive and specific for diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>